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EDITORIALOpening CFTR in the Intestine: Flushing on Demandnew paper by Cil et al1 has described the discoveryAand characterization of a small molecule capable of
opening the Cl- channel cystic ﬁbrosis transmembrane
regulator (CFTR). CFTR accounts for the majority of salt and
water secretion across mucosal surfaces and into the ducts
of secretory glands, and it is important for mucosal hydra-
tion in the intestine, lung, and cornea. The new channel
opener was identiﬁed from a library of 120,000 drug-like
synthetic compounds by using a high-throughput, single-
cell screen for agonists of Cl- transport. It is a phenyl-
quinoxalinone named CFTRactJ027.
The investigators tested the idea that CFTRactJ027 may
be applied clinically as a possible therapy for constipation.
Constipation remains a signiﬁcant and widespread clinical
problem. The mainstays of management for decades have
been various types of osmotic agents to hydrate the stool, or
gut motility–stimulating drugs. More recently, new drugs
have emerged that have sought to harness the natural
ﬂushing and lubrication mechanism in the intestine by
promoting transepithelial ﬂuid secretion. Prosecretory
drugs currently approved include linaclotide, a peptide
agonist of the guanylate cyclase C receptor, which activates
CFTR. The drug also activates the other cyclic-nucleotide
gated transporters responsible for the secretory response
(basolateral Kþ channels and the Naþ/Kþ/2Cl- cotrans-
porter NKCC1). Lubiprostone is a prostaglandin analog that
is thought to increase intracellular cyclic adenosine mono-
phosphate and activate CFTR along with the other cyclic-
nucleotide gated transporters in a similar way.
Unlike linaclotidea and lubiprostone, however,
CFTRactJ027 appears to act on CFTR alone, without affecting
other transporters, and without affecting intracellular
signaling intermediates such as the cyclic nucleotides. The
beneﬁt of direct action on the CFTR channel is clear: a
deﬁned mechanism of action, lower likelihood of side ef-
fects, and the possibility of mucosal targeting without sys-
temic absorption. However, there are some disadvantages
related to such a narrow scope of action. Cyclic guanosine
monophosphate agonists such as linaclotide and plecanatide
also modulate ascending sensory nerve pathways and
colonic motor pathways to inhibit visceral pain proprio-
ception and to promote motility. Both effects likely
contribute to the clinical efﬁcacy of these compounds in the
treatment of patients with irritable bowel syndrome or
other functional gastrointestinal disorders.
Still, the article by Cil et al1 outlines a number of prop-
erties that make CFTRactJ027 a promising candidate for
clinical applications. The investigators used a classic opioid
mouse model of constipation and showed that CFTRactJ027
is both highly speciﬁc and effective at improving con-
stipation. Strikingly, they showed that head-to-head, at least
in this mouse model, CFTRactJ027 is more effective thanCellular and Molecular Gastroenterology and Hepatology 2016;2:256both linaclotide and lubiprostone despite much higher
equivalent doses for these drugs than would be used clini-
cally. The study also described some initial pharmacology
and toxicity for CFTRactJ027, suggesting that the compound
may undergo rapid ﬁrst-pass metabolism, which likely
would limit (unwanted) systemic accumulation. The ﬂip
side of CFTR function is that prolonged and irreversible
activation of CFTR in the intestine causes the massive
secretory diarrhea seen in Vibrio cholerae and toxigenic
Escherichia coli infections. Fortunately, and perhaps because
of CFTRactJ027’s lack of action on the other pathways that
regulate and drive ﬂuid secretion, cholera-like diarrhea does
not occur after administration. In fact, by directly targeting
and opening CFTR, the compound primarily may potentiate
the normal physiological regulation of intestinal ﬂuid
secretion, although this remains to be proven.
Constipation-associated conditions such as constipation-
predominant irritable bowel syndrome and opioid-induced
constipation affect a large and growing proportion of the
US population. This study is therefore an important and
timely advance toward increasing the therapeutic options
for these disorders. There are still many hurdles to over-
come before application clinically. However, perhaps
CFTRactJ027, or another more reﬁned compound that opens
CFTR, will be found effective in treating constipation in
human beings. This would have a big impact.
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